Medicenna Therapeutics Corp (NASDAQ: MDNA) Reported Loss of $17.3 Million For The Year Ended March 31, 2021
Medicenna Therapeutics Corp (NASDAQ: MDNA) is an immuno-oncology company that announced the financial performance for the year ended March 31, 2021, where the company reported a loss of $17.3 million. In addition, the company guided the way for future growth. Besides this, the company also informed about the MDNA11 phase 1/ 2 study initiation on track. Reported loss; see promising future: During the year ended March 31, 2021, the company…